| Offering Information |
| Expected Date | TBA |
| Proposed Exchange/Ticker |
Nasdaq: BCLI |
| Security Type |
Common Stock |
| Lead Underwriter |
Not Applicable |
| Days In Registration |
- |
| Date Filed |
8-Feb-2013 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2012) |
| Industry |
Manufacturing |
| Business Description |
BrainStorm Cell Therapeutics Inc, based in New York, New York, is a biotechnology company focuses on developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinsons Disease (PD). |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
150.09M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
$15.0M |
| File Price Range |
- - - |
| File Mid Price |
- |
|
